Login / Signup

Serum 4β-hydroxycholesterol increases during fluconazole treatment.

Dieter LütjohannFrans StellaardAnja KerksiekJörn LötschBruno G Oertel
Published in: European journal of clinical pharmacology (2020)
Fluconazole inhibits the 14α-demethylation of lanosterol and 24,25-dihydrolanosterol, regulated by CYP51A1, without reduction of total cholesterol synthesis. The increased serum level of R_4β-hydroxycholesterol under fluconazole treatment is in contrast to the reductions observed under ketoconazole and itraconazole treatments. The question, whether this increase is caused by induction of CYP3A4 or by inhibition of the catabolism of 4β-hydroxycholesterol, must be answered by mechanistic in vitro and in vivo studies comparing effects of various azole antifungal agents on hepatic CYP3A4 activity.
Keyphrases
  • candida albicans
  • magnetic resonance
  • magnetic resonance imaging
  • replacement therapy
  • low density lipoprotein